Figure 4.

Cumulative incidences of the primary endpoint (major cardiovascular events) according to treatment in the multiple-country trial, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), before (A) and after standardizing to the imputed cohort (B) and the complete case cohort (C) among patients aged <80 years without selection weight truncation and with accounting for competing risk of any death. The cumulative incidence curves were plotted based on 20 imputed data sets (solid line for rosuvastatin group and dashed line for placebo group).